Introduction:

Zoledronic Acid improves the quality of life of patients suffering from prostate cancer.

Objectives:

To assess the health-related quality of life using EORTC QLQ-BM22 questioner in patients suffering from prostate cancer, treated with zoledronic acid.

Method:

A prospective-descriptive study was carried out in 71 patients suffering from prostate cancer involving bones, with ages ranging between 18 and 80 years, and who were treated in the oncology service at Hermanos Ameijeiras Hospital. The ECOG was less than 3, life expectancy> 6 months, and follow-up of at least twelve months. Zoledronic acid was administered every 21-28 days. The visual analog scale and EORTC QLQ-BM22 module were applied.

Results:

The patients had median age of 71 years, Gleason ≥ 8: in 57.7% of the patients, PSA at diagnosis ≥ 20 ng / mL: 70.4%, ECOG 1: 67.6%, and stage IV as initial presentation: 50.7%. Bone metastases without visceral intake: 84.5%, in vertebrae 36.6%, <3 sites 66.2%, and blast bone metastases 60.6%. Skeletal events related to zoledronic acid before 7.9% (fracture), and after 5.6% (anti-allergic radiotherapy). At twelve months, according to the visual analog scale, a complete response was achieved, 71%, and a partial response, 29% (p <0.05). After the application of EORTC QLQ-BM22 module, a significant decrease was found in both the symptom and functional scales, regardless of other factors.

Conclusions:

Specific treatments for prostate cancer combined with zoledronic significantly improve pain and health-related quality of life in patients with bone metastases.

        · resumen en Español     · texto en Español     · Español ( pdf )